Novel avenues for treating diabetic nephropathy: new investigational drugs

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Expert Opinion on Investigational Drugs

• Publication date

  2017-02-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/13543784.2017.1293039PMID 28277032
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CS-3150, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, Shows Preventive and Therapeutic Effects On Renal Injury in Deoxycorticosterone Acetate/Salt-Induced Hypertensive Rats

  2016cited by this paper
• Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial

  2016cited by this paper
• Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin‐angiotensin blockers

  2016cited by this paper
• Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin–Angiotensin System Blockade: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Trial

  2016cited by this paper
• Ruboxistaurin attenuates diabetic nephropathy via modulation of TGF‐β1/Smad and GRAP pathways

  2016cited by this paper
• Phosphodiesterase Type 5 Inhibition Reduces Albuminuria in Subjects with Overt Diabetic Nephropathy.

  2016cited by this paper
• JAK inhibition in the treatment of diabetic kidney disease

  2016cited by this paper
• Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR)α/γ agonist aleglitazar in attenuating TNF-α-mediated inflammation and insulin resistance in human adipocytes.

  2016cited by this paper
• A First‐in‐Patient, Multicenter, Double‐Blind, 2‐Arm, Placebo‐Controlled, Randomized Safety and Tolerability Study of a Novel Oral Drug Candidate, CTP‐499, in Chronic Kidney Disease

  2016influential reference
• An additive effect of eplerenone to ACE inhibitor on slowing the progression of diabetic nephropathy in the db/db mice.

  2016cited by this paper
• Vitamin D Receptor Down-Regulation Is Associated With Severity of Albuminuria in Type 2 Diabetes Patients.

  2016cited by this paper
• Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

  2016cited by this paper
• Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy.

  2015cited by this paper
• Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease

  2015cited by this paper
• Evaluating the Phase II drugs currently under investigation for diabetic neuropathy

  2015cited by this paper
• Allogeneic Mesenchymal Precursor Cells in Type 2 Diabetes: A Randomized, Placebo-Controlled, Dose-Escalation Safety and Tolerability Pilot Study

  2015cited by this paper
• Monoclonal antibodies for renal diseases: current concepts and ongoing treatments

  2015cited by this paper
• Role of Paricalcitol in Modulating the Immune Response in Patients with Renal Disease

  2015cited by this paper
• ASK1 Inhibitor Halts Progression of Diabetic Nephropathy in Nos3-Deficient Mice

  2015cited by this paper
• Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.

  2015cited by this paper
• Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial.

  2015influential reference
• Efficacy of aliskiren, compared with angiotensin II blockade, in slowing the progression of diabetic nephropathy in db/db mice: should the combination therapy be a focus?

  2015cited by this paper
• The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial.

  2015cited by this paper
• Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.

  2015cited by this paper
• Targeting NADPH oxidase with a novel dual Nox1/Nox4 inhibitor attenuates renal pathology in type 1 diabetes.

  2015cited by this paper
• Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

  2015cited by this paper
• New therapeutic strategies under development to halt the progression of renal failure

  2014cited by this paper
• Role of chemokines in proteinuric kidney disorders

  2014cited by this paper
• The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy.

  2014cited by this paper
• Generation and Activity of a Humanized Monoclonal Antibody That Selectively Neutralizes the Epidermal Growth Factor Receptor Ligands Transforming Growth Factor-α and Epiregulin

  2014cited by this paper
• Blocking ligand occupancy of the αVβ3 integrin inhibits the development of nephropathy in diabetic pigs.

  2014cited by this paper
• Mechanisms Contributing to Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease Treated with Bardoxolone Methyl

  2014cited by this paper
• Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study

  2014cited by this paper
• Sitagliptin Prevents Inflammation and Apoptotic Cell Death in the Kidney of Type 2 Diabetic Animals

  2014cited by this paper
• DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1α in type 2 diabetic patients with incipient nephropathy.

  2014cited by this paper
• Cilostazol effectively attenuates deterioration of albuminuria in patients with type 2 diabetes: a randomized, placebo-controlled trial

  2014cited by this paper
• Vitamin D Receptor Gene Polymorphism and Left Ventricular Hypertrophy in Chronic Kidney Disease

  2014cited by this paper
• The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.

  2013cited by this paper
• Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.

  2013cited by this paper
• CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice.

  2013cited by this paper
• Vitamin D metabolism and activity as well as genetic variants of the vitamin D receptor (VDR) in chronic kidney disease patients.

  2013cited by this paper
• Renal amyloidosis in cystic fibrosis: role of colchicine therapy

  2013cited by this paper
• Mesenchymal stem cells ameliorate podocyte injury and proteinuria in a type 1 diabetic nephropathy rat model.

  2013cited by this paper
• Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial.

  2013cited by this paper
• Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial.

  2013cited by this paper
• Rationale and Trial Design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON)

  2013cited by this paper
• PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy

  2013cited by this paper
• New Insights on the Role of Vitamin D in the Progression of Renal Damage

  2013cited by this paper
• Renal Effects of DPP-4 Inhibitors: A Focus on Microalbuminuria

  2013cited by this paper
• Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes.

  2013cited by this paper
• Autologous transplantation of adipose-derived mesenchymal stem cells ameliorates streptozotocin-induced diabetic nephropathy in rats by inhibiting oxidative stress, pro-inflammatory cytokines and the p38 MAPK signaling pathway.

  2012cited by this paper
• Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis

  2012cited by this paper
• Pharmacokinetic‐Pharmacodynamic Assessment of the Interrelationships Between Tesaglitazar Exposure and Renal Function in Patients With Type 2 Diabetes Mellitus

  2012cited by this paper
• Bindarit: an anti-inflammatory small molecule that modulates the NFκB pathway.

  2012cited by this paper
• An open label, randomized controlled study of oral calcitriol for the treatment of proteinuria in patients with diabetic kidney disease.

  2012cited by this paper
• Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo‐controlled crossover study

  2012cited by this paper
• Endothelin antagonists for diabetic and non‐diabetic chronic kidney disease

  2012cited by this paper
• Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin

  2012cited by this paper
• The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans.

  2012cited by this paper
• Autocrine modulation of glucose transporter SGLT2 by IL-6 and TNF-α in LLC-PK1 cells

  2012cited by this paper
• BsmI polymorphisms in vitamin D receptor gene are associated with diabetic nephropathy in type 2 diabetes in the Han Chinese population.

  2012cited by this paper
• Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy.

  2012cited by this paper
• Cardiorenal end points in a trial of aliskiren for type 2 diabetes.

  2012cited by this paper
• Oxidative Stress-Induced Diseases via the ASK1 Signaling Pathway

  2012cited by this paper
• Mesenchymal Stem/Stromal Cells (MSCs): Role as Guardians of Inflammation.

  2012cited by this paper
• Vitamin D receptor signaling in podocytes protects against diabetic nephropathy.

  2012cited by this paper
• Pyridorin in type 2 diabetic nephropathy.

  2012cited by this paper
• A dual CCR2/CCR5 chemokine antagonist, BMS-813160?

  2011cited by this paper
• Diabetic Nephropathy Amelioration by a Low-Dose Sitagliptin in an Animal Model of Type 2 Diabetes (Zucker Diabetic Fatty Rat)

  2011cited by this paper
• Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy.

  2011cited by this paper
• Vitamin D Status and Mortality Risk in Patients with Chronic Kidney Disease

  2011cited by this paper
• Sitagliptin reduces albuminuria in patients with type 2 diabetes.

  2011cited by this paper
• Oral cholecalciferol decreases albuminuria and urinary TGF-β1 in patients with type 2 diabetic nephropathy on established renin-angiotensin-aldosterone system inhibition.

  2011cited by this paper
• Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes

  2011cited by this paper
• Bardoxolone methyl and kidney function in CKD with type 2 diabetes.

  2011cited by this paper
• Pirfenidone for diabetic nephropathy.

  2011cited by this paper
• An orally active chemokine receptor CCR2 antagonist prevents glomerulosclerosis and renal failure in type 2 diabetes.

  2011cited by this paper
• Mineralocorticoid Receptor Blockade Enhances the Antiproteinuric Effect of an Angiotensin II Blocker through Inhibiting Podocyte Injury in Type 2 Diabetic Rats

  2010cited by this paper
• Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria.

  2010cited by this paper
• Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial.

  2010cited by this paper
• Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise

  2010cited by this paper
• Suppressors of cytokine signaling abrogate diabetic nephropathy.

  2010cited by this paper
• Potential new therapeutic agents for diabetic kidney disease.

  2010cited by this paper
• Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials.

  2010cited by this paper
• Colchicine attenuates inflammatory cell infiltration and extracellular matrix accumulation in diabetic nephropathy.

  2009cited by this paper
• Effect of treatment with losartan on salt sensitivity and SGLT2 expression in hypertensive diabetic rats.

  2009influential reference
• Enhanced Expression of Janus Kinase–Signal Transducer and Activator of Transcription Pathway Members in Human Diabetic Nephropathy

  2009cited by this paper
• Where are we with probucol: a new life for an old drug?

  2009cited by this paper
• Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy

  2009influential reference
• Anti-Glycation and Anti-Albuminuric Effects of GLY-230 in Human Diabetes

  2009cited by this paper
• Endovenous administration of bone-marrow-derived multipotent mesenchymal stromal cells prevents renal failure in diabetic mice.

  2009cited by this paper
• Pirfenidone is renoprotective in diabetic kidney disease.

  2009cited by this paper
• [Effect of pentoxifylline on the evolution of diabetic nephropathy].

  2009cited by this paper
• Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.

  2008cited by this paper
• Aliskiren combined with losartan in type 2 diabetes and nephropathy.

  2008cited by this paper
• Effects of three anti-TNF-alpha drugs: etanercept, infliximab and pirfenidone on release of TNF-alpha in medium and TNF-alpha associated with the cell in vitro.

  2008cited by this paper
• Reversal of proteinuric renal disease and the emerging role of endothelin

  2008cited by this paper
• Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function--evidence of interconversion.

  2008cited by this paper
• Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats.

  2008cited by this paper
• Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice.

  2008cited by this paper

• The therapeutic effect of mesenchymal stem cells in diabetic kidney disease

  2024cites this paper
• Insights Into the Functional Mechanism of Diabetic Kidney Disease Treatment with Sinensetin Based on Network Pharmacology and Molecular Docking

  2023cites this paper
• Network Pharmacology and Bioinformatics Methods Reveal the Mechanism of Sishenwan in the Treatment of diabetic nephropathy

  2023cites this paper
• Potential Medicinal Value of Rhein for Diabetic Kidney Disease

  2023cites this paper
• Stem cell-derived and circulating exosomal microRNAs as new potential tools for diabetic nephropathy management

  2022cites this paper
• The Aggressive Diabetic Kidney Disease in Youth-Onset Type 2 Diabetes: Pathogenetic Mechanisms and Potential Therapies

  2021cites this paper
• Role of Antioxidants in Oxidative Stress Associated Diseases

  2021cites this paper
• Low-intensity shockwave therapy in the treatment of diabetic nephropathy: a prospective Phase 1 study.

  2020cites this paper
• Antiproteinuric effect of DPP-IV inhibitors in diabetic and non-diabetic kidney diseases.

  2020cites this paper
• Diabetes Mellitus and Hypertension—A Case of Sugar and Salt?

  2020cites this paper
• Astragalus membranaceus and Panax notoginseng, the Novel Renoprotective Compound, Synergistically Protect against Podocyte Injury in Streptozotocin-Induced Diabetic Rats

  2019cites this paper
• Clinical Trials on Diabetic Nephropathy: A Cross-Sectional Analysis

  2019cites this paper
• Myricetin Attenuated Diabetes-Associated Kidney Injuries and Dysfunction via Regulating Nuclear Factor (Erythroid Derived 2)-Like 2 and Nuclear Factor-κB Signaling

  2019cites this paper
• Association of Higher Advanced Oxidation Protein Products (AOPPs) Levels in Patients with Diabetic and Hypertensive Nephropathy

  2019cites this paper
• Renal protective effect of Paeoniflorin by inhibition of JAK2/STAT3 signaling pathway in diabetic mice.

  2018cites this paper
• Animal Models of Diabetic Kidney Disease

  2018cites this paper
• Diabetic Nephropathy Can Be Treated with Calcium Dobesilate by Alleviating the Chronic Inflammatory State and Improving Endothelial Cell Function

  2018cites this paper
• Preventing and treating kidney disease in patients with type 2 diabetes

  2018cites this paper
• Exploring the effects of DPP‐4 inhibitors on the kidney from the bench to clinical trials

  2017cites this paper
• Antioxidant agents for delaying diabetic kidney disease progression: A systematic review and meta-analysis

  2017cites this paper
• Thrombospondin-1 regulation of latent TGF-β activation: A therapeutic target for fibrotic disease.

  2017cites this paper
• BIOLOGICAL IMPACT OF METFORMIN VERSUS THIAZOLIDINEDIONE ON ALVEOLAR BONE OF INDUCED DIABETIC RATS (A HISTOLOGICAL AND IMMUNO-HISTOMORPHOMETRIC STUDY).

  2017cites this paper
• AT2 receptor agonist Compound 21: A silver lining for diabetic nephropathy

  2017cites this paper